CNS Pharmaceuticals Closes $1.5M Private Placement

Ticker: CNSP · Form: 8-K · Filed: 2025-01-03T00:00:00.000Z

Sentiment: neutral

Topics: private-placement, funding, clinical-trials

TL;DR

CNS Pharma raised $1.5M in a private placement to fund clinical trials.

AI Summary

On January 3, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several events. The company announced the closing of a private placement of its common stock, raising approximately $1.5 million before expenses. This funding is intended to support ongoing clinical trials and general corporate purposes.

Why It Matters

This capital infusion provides CNS Pharmaceuticals with crucial funding to advance its clinical development programs, potentially accelerating the path to market for its drug candidates.

Risk Assessment

Risk Level: medium — While the funding is positive, the company is still in the clinical trial phase, indicating inherent risks associated with drug development and regulatory approval.

Key Numbers

Key Players & Entities

FAQ

What was the gross amount raised in the private placement?

The filing indicates the company raised approximately $1.5 million before expenses.

What is the intended use of the proceeds from the private placement?

The proceeds are intended to support ongoing clinical trials and for general corporate purposes.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on January 3, 2025.

What is the state of incorporation for CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. is incorporated in Nevada.

What is the company's principal executive office address?

The principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.

Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-03 17:00:34

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 3, 2025, CNS Pharmaceuticals, Inc. (the "Company") posted the investor presentation set forth in Exhibit 99.1 on its website. The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

01 Other Events

Item 8.01 Other Events Subsequent to the filing of the Company's Form 10-Q for the quarter ended September 30, 2024, the Company has sold 17,475,827 shares of common stock pursuant to its at-the-market sales agreement. As of January 3, 2025, the Company has 74,962,533 shares of common stock outstanding.

01 Financial Statements

Item 9.01 Financial Statements and Exhibits No. Description 99.1 Presentation dated January 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: January 3, 2025 3

View on Read The Filing